These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33442968)

  • 1. In Brief: New warnings on NSAID use in pregnancy.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):175. PubMed ID: 33442968
    [No Abstract]   [Full Text] [Related]  

  • 2. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
    Bradford WD; Kleit AN
    Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available.
    Young D
    Am J Health Syst Pharm; 2005 Apr; 62(7):668-72. PubMed ID: 15790792
    [No Abstract]   [Full Text] [Related]  

  • 5. In Brief: New benzodiazepine warnings.
    Med Lett Drugs Ther; 2020 Nov; 62(1610):175. PubMed ID: 33429404
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries of safety labeling changes approved by FDA-Boxed Warnings Highlights October-December 2014.
    Rubio T
    Am J Health Syst Pharm; 2015 Mar; 72(5):343. PubMed ID: 25694404
    [No Abstract]   [Full Text] [Related]  

  • 7. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
    Am J Health Syst Pharm; 2016 Jun; 73(11):e375-7. PubMed ID: 27208062
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease.
    Pirlamarla P; Bond RM
    Trends Cardiovasc Med; 2016 Nov; 26(8):675-680. PubMed ID: 27238053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries of safety labeling changes approved by FDA-boxed warnings highlights January-March 2016.
    Am J Health Syst Pharm; 2016 Jun; 73(11):739-40. PubMed ID: 27208054
    [No Abstract]   [Full Text] [Related]  

  • 10. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 11. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1998 Dec; 280(21):1817. PubMed ID: 9846762
    [No Abstract]   [Full Text] [Related]  

  • 12. Mifepristone label laws and trends in use: recent experiences in four US states.
    Sheldon WR; Winikoff B
    Contraception; 2015 Sep; 92(3):182-5. PubMed ID: 26116033
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin, salicylates, and nonsteroidal anti-inflammatory drugs: new class labeling and medical practice.
    Roth SH
    Compr Ther; 1991 Jun; 17(6):15-21. PubMed ID: 1934983
    [No Abstract]   [Full Text] [Related]  

  • 14. From qualified physician to licensed health care professional: the time has come to change mifepristone's label.
    Foster AM; Jackson CB; LaRoche KJ; Simmonds K; Taylor D
    Contraception; 2015 Sep; 92(3):200-2. PubMed ID: 26134281
    [No Abstract]   [Full Text] [Related]  

  • 15. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments.
    Fed Regist; 1999 Sep; 64(177):49652-5. PubMed ID: 10915461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib approved as NSAID with some concessions on class warning.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):403. PubMed ID: 10096694
    [No Abstract]   [Full Text] [Related]  

  • 18. Off-label prescribing. Legal implications.
    Henry V
    J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
    [No Abstract]   [Full Text] [Related]  

  • 19. Hot topics in pain management: using NSAIDs safely.
    D'Arcy Y
    Nursing; 2006 Feb; 36(2):22-3. PubMed ID: 16462239
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.